This Persistence Market Research (PMR) report examines the ‘Global RNA-based Therapeutics and Vaccines Market for the period 2019–2026. The primary objective of the report is to offer updates and information related to market opportunities in the global RNA-based Therapeutics and Vaccines Market.
The RNA-based Therapeutics and Vaccines Market is Segmented as Follows:
This report covers the global RNA-based Therapeutics and Vaccines Market performance in terms of revenue contribution from various segments. The report begins with an overview of the RNA-based Therapeutics and Vaccines Market and its definitions. The market viewpoints section underlines macro-economic factors influencing the growth of the RNA-based Therapeutics and Vaccines Market along with detailing its opportunity analysis.
The global RNA-based Therapeutics and Vaccines Market is segmented based on product type, indication and region. On the basis of product type, the market has been segmented as RNA-based Therapeutics and RNA-based Vaccines (mRNA).
On the basis of indication, the market is segmented as Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, genetic diseases & others.
A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, & absolute $ opportunity. The regional market dynamics provide the key growth driver, restraints, and trends pertaining to each region. The forecast of the RNA-based Therapeutics and Vaccines Market by country, product type, indication are represented in the tabular form for each region. This section also helps to understand the opportunity of the RNA-based Therapeutics and Vaccines Market in major countries by each segment.
In the next section of the report, the ‘Competitive Landscape’ is included to provide report audiences with a dashboard view and to access the key differentiators among the competitor firms. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product development and strategies of key providers specific to the market segments. Detailed profiles of players in the RNA-based Therapeutics and Vaccines Market are also provided in the report, which highlights company description, product/segment overview, SWOT analysis, key developments related to market and strategic overview.
The next section of the report highlights the market outlook for 2019–2026 and sets the forecast within the context of the RNA-based Therapeutics and Vaccines Market by region. The key regions assessed in this report include North America, Latin America, Europe, Asia Pacific and MEA. A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate and absolute $ opportunity.
The above sections – by product type, indication– evaluate the growth prospects of the RNA-based Therapeutics and Vaccines Market for the period 2019–2026. We have considered 2017 as the base year and provided data for the forecast period.
The final section of report represents the global scenario for the RNA-based Therapeutics and Vaccines Market along with Y-o-Y growth and market forecast till 2026. This section also evaluates the global market opportunity over the forecast period and also the absolute dollar opportunity for each year. This section will help to understand the overall market growth of the RNA-based Therapeutics and Vaccines Market and the opportunity analysis for each year over the forecast period.
Bottom-up approach is used to validate the total market size obtained. The forecast presented in the report provides total revenue of the RNA-based Therapeutics and Vaccines Market over 2019–2026. While forecasting the market size, we have considered the impact of several factors such product approvals for RNA-based Therapeutics and Vaccines Market, R&D investment by major players, pipeline analysis, penetration of products in different distribution channel, etc. However, quantifying the market across the aforementioned segments and regions is more a matter of quantifying expectations and identifying opportunities rather than rationalizing them after the forecast has been completed. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market.
Global Study on RNA based Therapeutics and Vaccines Market: siRNA Product Type Segment Projected to Witness the Highest market share through 2026
RNA based Therapeutics and Vaccines Market Value and Forecast
The global RNA based Therapeutics and Vaccines market is expected to be account US$ 632.06 Mn in 2026, it is projected to increase at a CAGR of 70.4% through 2026. North America is large RNA based Therapeutics and Vaccines, which accounted for US$ 8.99 Mn in 2019, and is expected to grow at a CAGR of 61.5%.
RNA based Therapeutics and Vaccines Key Insights
RNA based Therapeutics and Vaccines Factors and Trends Impacting the Growth of the Market
RNA’s molecules are high unstable inside the body environment with limited bioavailability. In-order to increase the stability and bioavailability, RNA therapeutics are conjugated with lipid/protein nanoparticles. For example: SNALP (stable nucleic acid lipid particles): - SNALP is bi-layered mixture of fusogenic and cationic lipids and it enhances endosomal release and cellular uptake. Patisiran (ALN-TTR02) drug is in registration process and it is formulated as SNALP (stable nucleic acid lipid particles) with application route of Intravenous. AtuPLEX (liposome) with AtuRNAi (2′-O-Me): - Cationic liposomes are intended to improve the stability of oligonucleotides. Atu027 drug is in Phase 2 clinical trial and it is formulated as AtuPLEX (liposome) with AtuRNAi (2′-O-Me) with application route of Subcutaneous. The study is completed.
Manufacturers are mostly focused on collaborations and partnerships in-order to keep the pace of research activities when compared with competitors. Because of these collaborative agreements, innovators are supplemented with advanced technologies and financial resources.
For example: In March 2018, Regeneron Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. entered into collaboration to develop RNAi therapeutics for the chronic liver disease non-alcoholic steatohepatitis (NASH) and potentially other related diseases. In Oct 2017, Arbutus Biopharma Corporation and Gritstone Oncology entered into collaboration and license agreement. Arbutus is deploying its proprietary lipid nanoparticle (LNP) technology to deliver Gritstone’s RNA-based neoantigen immunotherapy products.
RNA based Therapeutics and Vaccines Regional Outlook
The global RNA based Therapeutics and Vaccines market is segmented into the key regions, namely North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. In terms of value, North America is a large market and is expected to increase at over 61.5% CAGR during the forecast period. The Asia Pacific RNA based Therapeutics and Vaccines market is projected to show fast growth and it is projected grow at CAGR of 93.9% over the forecast period.
RNA based Therapeutics and Vaccines Key Players
Examples of some of the key players operating in the global RNA based Therapeutics and Vaccines market are Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corp., Arrowhead Pharmaceuticals, Inc., BioNTech AG, CureVac AG, Dicerna Pharmaceuticals, Inc., Regulus Therapeutics, Inc., Marina Biotech, Inc., miRagen Therapeutics, Moderna Therapeutics, Inc., Quark Pharmaceuticals, Inc., Santaris Pharma A/S (A Roche Company), & Sylentis S.A.